$5.95
Live
0.84%
Downside
Day's Volatility :6.5%
Upside
5.71%
3.7%
Downside
52 Weeks Volatility :68.43%
Upside
67.22%
Period | Neuropace Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.42% | 3.6% | 0.0% |
6 Months | -53.79% | 10.2% | 0.0% |
1 Year | -0.77% | 19.6% | 0.0% |
3 Years | -58.01% | 16.8% | -23.0% |
Market Capitalization | 186.6M |
Book Value | $0.34 |
Earnings Per Share (EPS) | -1.08 |
Wall Street Target Price | 15.5 |
Profit Margin | -41.63% |
Operating Margin TTM | -32.35% |
Return On Assets TTM | -15.75% |
Return On Equity TTM | -192.19% |
Revenue TTM | 71.8M |
Revenue Per Share TTM | 2.61 |
Quarterly Revenue Growth YOY | 16.6% |
Gross Profit TTM | 32.5M |
EBITDA | -24.6M |
Diluted Eps TTM | -1.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.09 |
EPS Estimate Next Year | -1.05 |
EPS Estimate Current Quarter | -0.3 |
EPS Estimate Next Quarter | -0.28 |
What analysts predicted
Upside of 160.5%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 37.0M | - |
Net Income | -40.7M | - |
Net Profit Margin | -110.19% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 41.1M | ↑ 11.27% |
Net Income | -36.0M | ↓ 11.68% |
Net Profit Margin | -87.47% | ↑ 22.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 45.2M | ↑ 9.83% |
Net Income | -38.1M | ↑ 5.91% |
Net Profit Margin | -84.34% | ↑ 3.13% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 45.5M | ↑ 0.75% |
Net Income | -53.4M | ↑ 40.05% |
Net Profit Margin | -117.25% | ↓ 32.91% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 65.4M | ↑ 43.72% |
Net Income | -33.0M | ↓ 38.25% |
Net Profit Margin | -50.38% | ↑ 66.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.5M | ↑ 13.16% |
Net Income | -14.4M | ↑ 15.79% |
Net Profit Margin | -99.47% | ↓ 2.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.5M | ↑ 14.08% |
Net Income | -9.1M | ↓ 36.62% |
Net Profit Margin | -55.26% | ↑ 44.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.4M | ↓ 0.5% |
Net Income | -7.3M | ↓ 20.46% |
Net Profit Margin | -44.18% | ↑ 11.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.0M | ↑ 9.65% |
Net Income | -6.2M | ↓ 14.57% |
Net Profit Margin | -34.42% | ↑ 9.76% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 18.1M | ↑ 0.62% |
Net Income | -8.9M | ↑ 43.95% |
Net Profit Margin | -49.24% | ↓ 14.82% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 19.3M | ↑ 6.25% |
Net Income | -7.5M | ↓ 15.81% |
Net Profit Margin | -39.02% | ↑ 10.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 21.1M | - |
Total Liabilities | 150.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 56.0M | ↑ 165.23% |
Total Liabilities | 203.8M | ↑ 35.45% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 133.6M | ↑ 138.72% |
Total Liabilities | 60.1M | ↓ 70.53% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 114.1M | ↓ 14.57% |
Total Liabilities | 79.3M | ↑ 32.09% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 107.7M | ↓ 5.66% |
Total Liabilities | 87.0M | ↑ 9.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.3M | ↓ 6.87% |
Total Liabilities | 78.8M | ↓ 0.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 102.2M | ↓ 3.8% |
Total Liabilities | 81.0M | ↑ 2.82% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 99.3M | ↓ 2.87% |
Total Liabilities | 82.9M | ↑ 2.38% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 107.7M | ↑ 8.41% |
Total Liabilities | 87.0M | ↑ 4.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 98.9M | ↓ 8.17% |
Total Liabilities | 84.5M | ↓ 2.86% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 94.4M | ↓ 4.52% |
Total Liabilities | 84.5M | ↓ 0.01% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.0M | - |
Investing Cash Flow | 3.6M | - |
Financing Cash Flow | 21.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.6M | ↓ 13.65% |
Investing Cash Flow | -10.8M | ↓ 397.6% |
Financing Cash Flow | 55.0M | ↑ 157.41% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.6M | ↑ 13.74% |
Investing Cash Flow | -85.4M | ↑ 693.13% |
Financing Cash Flow | 102.5M | ↑ 86.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.9M | ↑ 50.01% |
Investing Cash Flow | 23.8M | ↓ 127.87% |
Financing Cash Flow | 490.0K | ↓ 99.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↑ 23.65% |
Investing Cash Flow | 10.1M | ↑ 13.15% |
Financing Cash Flow | -255.0K | ↑ 84.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.4M | ↓ 55.04% |
Investing Cash Flow | 5.3M | ↓ 47.36% |
Financing Cash Flow | 195.0K | ↓ 176.47% |
Sell
Neutral
Buy
Neuropace Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Neuropace Inc | -10.39% | -53.79% | -0.77% | -58.01% | -74.08% |
Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Neuropace Inc | NA | NA | NA | -1.09 | -1.92 | -0.16 | NA | 0.34 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Neuropace Inc | Buy | $186.6M | -74.08% | NA | -41.63% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Neuropace Inc
Revenue is up for the last 4 quarters, 16.42M → 19.25M (in $), with an average increase of 5.1% per quarter
Netprofit is up for the last 2 quarters, -8.92M → -7.51M (in $), with an average increase of 18.8% per quarter
In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 82.0%
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 154.3%
Orbimed Advisors, LLC
Morgan Stanley - Brokerage Accounts
Soleus Capital Management, L.P.
Nantahala Capital Management, LLC
Kent Lake Capital LLC
Vanguard Group Inc
the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
Organization | Neuropace Inc |
Employees | 179 |
CEO | Mr. Joel D. Becker |
Industry | Healthcare |